Restenosis Clinical Trial
Official title:
Butylphthalide for Preventing Restenosis After Intracranial and Extracranial Artery Stenting
The purpose of this study is to determine whether butylphthalide are effective for Preventing Restenosis after Intracranial and Extracranial Artery Stenting
Ischemic stroke is a significant cause of death, most of the patients is caused by atherosclerosis,current treatments include internal medicine medications, interventional treatment and so on,among them, the interventional therapy can make narrow blood vessels blood recovery fastly,and for its small trauma,Gradually accepted by psychiatrist, But stents are easy to narrow has been plagued by everybody ,At present, prevent restenosis stent is mainly of antiplatelet therapy,But,prevention effect is not obvious often easy to appear harmful response,how to effectively reduce postoperative restenosis, become the majority concern of patients and doctors .Clinical trials showed that, butylbenzene can promote the function of ischemic stroke recovery patients. Animal pharmacodynamics study suggests that this product can block the ischemic stroke of brain damage caused by DuoGe pathological link, with strong against ischemic and brain protection, especially can obviously increase in small brains ischemia ATP and phosphoric acid creatine level, decrease local cerebral ischemia in rats, reduce infarct size, cerebral edema improved energy metabolism and brain ischemia of microcirculation and blood flow in the brain, restrain the nerve cell apoptosis, and has the cerebral thrombosis and anti-platelet aggregation function. Research shows that, butylbenzene phthalocyanine influence through arachidonic acid (AA) metabolism, selective inhibition and their metabolites from DuoZhong mediated pathophysiological events, can remove microvascular spasms. Inhibit platelet aggregation, restrain TXA2 synthesis, scavenging free radicals, thereby through many ways, many link blocking caused by cerebral ischemia the pathophysiology of development process. These mechanisms may make butylbenzene in preventing phthalocyanine intracranial carotid stenting noted restenosis and related ischemia of events play an important role. ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01970579 -
Clinical Trial on Peripheral Arteries Treated With SeQuent® Please P Paclitaxel Coated Balloon Catheter
|
Phase 3 | |
Completed |
NCT01861860 -
OPtimized Stenting Using Intravascular Ultrasound(IVUS) in Long lEsion: Rationale for Simplified criteriA
|
N/A | |
Completed |
NCT01722877 -
JetStream (JS) Atherectomy in Femoropopliteal In-Stent Restenotic Lesions
|
N/A | |
Recruiting |
NCT00774917 -
Numen Stent Assessment Using OCT Technique in a Single Center Study
|
Phase 2/Phase 3 | |
Completed |
NCT00647504 -
Prospective Clinical Observational Registry Including Consecutive Patients With In-stent Restenosis or Stent Thrombosis
|
N/A | |
Completed |
NCT00493597 -
Blood Endothelium Progenitor Cells and Dendritic Cells as Predictive Biomarkers of In-stent Restenosis
|
||
Not yet recruiting |
NCT01476020 -
Is There A LIfe for Drug Eluting Stent (DES) After Discontinuation of Clopidogrel
|
Phase 3 | |
Terminated |
NCT00780156 -
The ITALIC Study: Is There A LIfe for Drug-eluting Stents (DES) After Discontinuation of Clopidogrel
|
N/A | |
Terminated |
NCT00712257 -
Study to Evaluate the Safety and Performance of Spectranetics Laser w/Adjunct PTA and Gore Viabahn Endoprosthesis for Treatment of SFA Instent Restenosis
|
N/A | |
Completed |
NCT01065532 -
SEDUCE OCT Study in Coronary Artery rEstenosis:an Optical Coherence Tomography (OCT) Study
|
N/A | |
Recruiting |
NCT03613337 -
Effect of Smoking Status and Genetic Risk Factors on Restenosis and Efficacy of Clopidogrel After de Novo Percutaneous Coronary Intervention
|
||
Completed |
NCT03332264 -
Sequent Please Drug Coated Balloons Versus Primary Stent Application in Long SFA Lesions
|
N/A | |
Completed |
NCT02063672 -
Lutonix® Drug Coated Balloon vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis
|
N/A | |
Recruiting |
NCT05451368 -
Neointimal Features in Patients With Restenosis of Calcified Lesions
|
||
Completed |
NCT02649946 -
Clinical Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft
|
N/A | |
Completed |
NCT01632371 -
Intracoronary Stenting and Angiographic Results: Optimizing Treatment of Drug Eluting Stent In-Stent Restenosis 4
|
Phase 4 | |
Completed |
NCT00798954 -
Treatment of Bifurcation Lesions by SINGLE STENT and KISSing Balloon Trial
|
Phase 4 | |
Withdrawn |
NCT03146221 -
Search for Restenosis Markers in Lower Limb Arteritis
|
N/A | |
Completed |
NCT02790606 -
Clinical Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft in AV Graft Patients (AVeVA)
|
N/A | |
Completed |
NCT00987324 -
Efficacy Study of Paclitaxel-eluting Balloon, -Stent vs. Plain Angioplasty for Drug-eluting Stent Restenosis
|
Phase 4 |